LIANYUNGANG, China, April 25, 2016 /PRNewswire/ -- Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced today that they have entered into a research agreement with Albert Einstein College of Medicine (Einstein) to advance cancer treatment. The multi-year cancer research agreement brings together the scientific and clinical capabilities of Einstein and Jiangsu Hengrui Medicine to develop innovative cancer therapies. The immediate goal of this research is to discover new targets and develop therapies in oncology space.
Dr. Guoqing Cao, Vice President of Jiangsu Hengrui Medicine, commented: "Einstein is a prominent medical research institute with a long track record of achievements in advancing cancer research and fighting cancer. Hengrui is very pleased to partner with Einstein to develop innovative oncology therapies. The collaboration will further strengthen Hengrui's leading position as the oncology drug developer in China."
The collaboration with Jiangsu Hengrui Medicine is the first between Einstein and a China based pharmaceutical company.
About Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual net sales of over U.S. $1.2 billion. Hengrui's products and innovative R&D span multiple therapeutic areas, including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and inflammation. Visit http://www.hrs.com.cn for further information.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jiangsu-hengrui-medicine-announce-collaboration-with-albert-einstein-college-of-medicine-to-advance-cancer-research-and-drug-discovery-300256823.html
SOURCE Jiangsu Hengrui Medicine Co., Ltd